TempraMed

TempraMed Overview

TempraMed developed a patent protected technology that can be used in a wide range of Medical/Consumer products, providing temperature control without need for power source or human intervention for years and additionally track medication use. TempraMed already sells products to the first vertical, addressing the need to provide temperature control and management to temperature sensitive injectable medications such as Insulin, EpiPen, Biologics, Hormone, to patients worldwide – a growing market opportunity. TempraMed’ s product addresses the need of patients, HCP, and payors to make sure medications are tracked and controlled to maintain their potency. While initial target customers for the products are the patients as the products become the standard, they will be adopted by the payors and pharmaceutical companies. The technology used allow the products to be very small and lightweight. Its smart thermal shield combines a unique ultrahigh vacuum thermal insulation and a small amount of heat absorbing phase change material and uses our unique thermal design. This combination blocks and absorbs heat during the entire day time, and releases the absorbed heat back to the environment overnight, regaining its heat absorbing capacity for the following day, without any intervention.

Cumulative Funding Raised Over Time ($)

Latest News

Oct 27, 2025 · finance.yahoo.com

growth-positive

TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon

TempraMed Technologies Ltd., a leader in temperature-controlled medication storage solutions, has announced an in-kind partnership with Beyond Type 1 for the 2025 TCS New York City Marathon initiative, Beyond Type Run. This partnership supports 55 runners, many living with diabetes, by ensuring their medications are protected during the marathon. TempraMeds involvement aligns with its mission to empower the diabetes community through innovation and advocacy. The company offers FDA-registered products like VIVI Cap and VIVI Epi, and is expanding its smart technology platform. This partnership highlights TempraMeds commitment to enhancing medication protection and adherence globally.

Partners

Oct 21, 2025 · finance.yahoo.com

growth-positive

TempraMed Announces Private Placement of up to C$2.5 Million

TempraMed Technologies Ltd., a leader in temperature-controlled medication storage solutions, announced a non-brokered private placement to raise up to C$2.5 million. The funds will be used for new inventory, product development, and scaling the sales and marketing division globally. Each unit in the offering includes one common share and one share purchase warrant, with the warrant allowing the purchase of an additional share at C$1.00 within 18 months. The closing of the offering is expected by November 5, 2025. TempraMeds products, such as VIVI Cap and VIVI Epi, are FDA-registered and designed to maintain the effectiveness of temperature-sensitive medications.

Investment

Oct 15, 2025 · finance.yahoo.com

growth-positive

Canadian Securities Exchange Welcomes Listing of TempraMed Technologies Ltd.

TempraMed Technologies Ltd., an Israeli company specializing in temperature-controlled medication storage solutions, has been listed on the Canadian Securities Exchange (CSE) under the ticker symbol VIVI. The company completed a C$7.4 million private placement, issuing approximately 51.7 million common shares. This public listing is expected to provide TempraMed with access to a broader community of investors and valuable growth capital, enabling the company to accelerate its global expansion. TempraMeds innovative solutions aim to help pharmacies and customers manage temperature-sensitive medications effectively. The listing marks a significant milestone in the companys journey, as it joins the CSEs cohort of emerging life sciences companies.

PIPE/PO

Oct 13, 2022 · www.prnewswire.com

growth-positive

New VIVI Epi device from TempraMed affords first-of-its-kind case protection for EpiPens against light and temperatures extremes

TempraMed is introducing the VIVI Epi, a new protection device for the EpiPen. The device is designed to protect Epinephrine from extreme temperatures and light. It will provide all-day, go anywhere protection for millions of allergy sufferers. The VIVI Epi will also be useful for institutions that need emergency interventions for anaphylactic events. The device meets the criteria for storing Epinephrine and is TSA compliant. It uses thermal insulation and control electronics to prevent degradation of the medication. TempraMeds mission is to create hassle-free solutions that help patients live better lives.

Customers

Sep 15, 2022 · www.biospace.com

growth-positive

TempraMed introduces new-generation insulin protection device with first and only reusable temperature shield Cap | BioSpace

TempraMed is launching a new-generation insulin pen-cap temperature shield called VIVI Cap multi-model. The product provides temperature protection for in-use insulin, ensuring its efficacy and convenience for patients with diabetes. The VIVI Cap is self-contained, lightweight, and easy to use, with a built-in temperature sensor and indicator. It fits in a purse or pocket, allowing patients to carry it anywhere. The shield prevents insulin from being compromised by extreme temperatures, which can reduce its effectiveness and lead to adverse side effects. The VIVI Cap uses special thermal insulation and control electronics to maintain the temperature. TempraMed aims to create hassle-free solutions that help patients live better lives by protecting their medication.

Customers

Funding

Team Members

3

Employees: 11-50

Web & Social Links

Locations

He Be'Iyar 64, Tel Aviv-Yafo, Israel

19481 SE 14st Sammamish WA, USA

Photos & Videos

6 item(s)

TempraMed Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info